Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.

求助中 10 由 TI__ME 发布于 2026/10/30 1:39:37

DOI:10.1016/S2213-8587(26)00133-6
作者：Lixin Guo,?Xiaolei Bao,?Kuo-Chin Huang,?Kristoffer Jensen Kolnes,?Christian Laugesen,?Yibing Lu,?Bifen Luo,?Guoyue Yuan,?Robert F Kushner
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Semaglutide 2·4 mg is a GLP-1 receptor agonist that reduces bodyweight, and provides other cardiometabolic benefits, among people with a BMI at least 30 kg/m2 or at least 27 kg/m

应助信息

等您来应助

上传文件

2小时前

Book学术机器人

2026/10/30 1:39:38 未找到该文献，机器人已退出，请等待人工下载

2026/10/30 1:39:37 Book学术AI机器人收到请求，开始寻找文献

2026/10/30 1:39:37 已向机器人发送请求

2小时前

TI__ME 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierMulti-frequency vortex-induced vibrations of a long tensioned beam in linear and exponential shear flows